Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the ...

Hims & Hers Health Inc. won’t back down from selling cheap weight-loss shots, its chief executive officer said one day after Novo Nordisk A/S abruptly ended its distribution partnership. “We’re upset ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

The loss of Novo’s involvement significantly dented investor confidence in Hims & Hers, plunging shares in the latter by 35% ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Novo Nordisk A/S has scrapped a partnership with Hims & Hers Health Inc after less than two months, saying the US company is ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...